Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
32.14
-0.15 (-0.46%)
Jan 22, 2026, 3:56 PM EST - Market open
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $70.57M in the quarter ending September 30, 2025, with 81,958.14% growth. This brings the company's revenue in the last twelve months to $789.00K, up 161.26% year-over-year. In the year 2024, Viridian Therapeutics had annual revenue of $302.00K, down -3.82%.
Revenue (ttm)
$789.00K
Revenue Growth
+161.26%
P/S Ratio
37.05
Revenue / Employee
$495,028
Employees
143
Market Cap
3.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | 4.46M | -3.93M | -46.80% |
| Dec 31, 2018 | 8.39M | 4.38M | 109.49% |
| Dec 31, 2017 | 4.00M | 526.00K | 15.13% |
| Dec 31, 2016 | 3.48M | 939.00K | 37.00% |
| Dec 31, 2015 | 2.54M | -1.78M | -41.25% |
| Dec 31, 2014 | 4.32M | 4.00K | 0.09% |
| Dec 31, 2013 | 4.32M | -90.04K | -2.04% |
| Dec 31, 2012 | 4.41M | 2.49M | 130.01% |
| Dec 31, 2011 | 1.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Catalyst Pharmaceuticals | 578.20M |
| Tarsus Pharmaceuticals | 366.10M |
| Arcutis Biotherapeutics | 317.93M |
| IDEAYA Biosciences | 214.83M |
| Liquidia | 69.22M |
| Beam Therapeutics | 55.70M |
| Centessa Pharmaceuticals | 15.00M |
| Xenon Pharmaceuticals | 7.50M |
VRDN News
- 13 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 16 days ago - Viridian Therapeutics Prepares for Transformational 2026 - Business Wire
- 4 weeks ago - Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire
- 5 weeks ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 2 months ago - Viridian Therapeutics Is Ready For An Eventful 2026 - Seeking Alpha
- 2 months ago - Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire
- 2 months ago - Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease - Business Wire
- 3 months ago - Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock - Business Wire